Search

It has been a long time that neoadjuvant chemotherapy is applied to breast cancer, but the effects on its prognosis are unclear. According to the current data, it is suggested that the neoadjuvant chemotherapy for breast cancer has long-term benefits in patients without infiltrating carcinoma in lymph nodes and axillary, and without pathological invasive cancer and carcinoma in situ. For patients with more aggressive breast cancer subtypes, even the outcome is pathological complete remission, they still have the high risk of recurrence and metastasis. Currently, there is no data to focus on the several clinical trials about the continue therapy in situ residuals in breast cancer. We expand on the ongoing research focusing on in situ residuals in breast cancer, which will provide reference for further clinical development of this therapy. [ABSTRACT FROM AUTHOR]